Key Highlights
- Jason Tardio appointed as COO and President of Immunic, Inc.
- Will lead efforts for potential launch of vidofludimus calcium (IMU-838).
- Brings extensive experience from Novartis and Biogen.
- Promotion of Werner Gladdines to Chief Development Officer.
Source: PR Newswire
Notable Quotes
- “Jason’s extensive experience, most notably related to the launch and commercialization of successful multiple sclerosis (MS) drugs for both Novartis and Biogen, as well as his history of significant out-licensing transactions provide Immunic with an invaluable and proven skill as we draw closer to completion of vidofludimus calcium’s phase 3 ENSURE program.” — Daniel Vitt, Ph.D., Chief Executive Officer at Immunic
- “I am thrilled to join Immunic’s very talented team and am particularly enthusiastic about the potential to bring such a groundbreaking and much-needed oral treatment option to patients with relapsing and also progressive forms of MS.” — Jason Tardio, Chief Operating Officer and President at Immunic
SoHC's Take
The appointment of Jason Tardio as Chief Operating Officer and President marks a pivotal moment for Immunic, Inc. With his robust background in the biopharmaceutical industry, particularly in the commercialization of multiple sclerosis therapies, Tardio is well-equipped to lead the launch of vidofludimus calcium. This strategic move underscores Immunic’s commitment to advancing their clinical pipeline and enhancing their market readiness. The concurrent promotion of Werner Gladdines further strengthens the leadership team, ensuring comprehensive oversight of clinical operations. Immunic’s proactive approach in bolstering its executive team reflects its dedication to addressing unmet medical needs in chronic inflammatory and autoimmune diseases.
